BioSpace News Archive

It has been thought that llamas may hold the key to developing an effective therapeutic against COVID-19, as well as the flu. This morning, scientists from the National Institutes of Health made additional headway in llama research, isolating promising antibodies from the South American animal.

Hutchison China MediTech Limited announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Healthcare Conference taking place virtually on Monday January 11, 2021 at 8 a.m. EST.

Ultimovacs ASA, announced the initiation of FOCUS, a Phase II randomized clinical trial that will evaluate the Company’s proprietary universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab.

LSBio, a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast.

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, announces the recruitment of the first patient of its phase 2 GARDEN study to treat COVID-19 _related acute respiratory distress syndrome with glenzocimab.

Leading Healthcare Facility in South Korea Helps Advance the Practice of MRI-Guided Radiation Therapy Through Research, Protocols, and Publications

Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results for its pivotal Phase 3 DOM-INNATE

Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Denice Torres, J.D., to its Board of Directors effective December 22, 2020.

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced positive topline results from a pivotal Phase 3 clinical trial evaluating setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, for the treatment of insatiable hunger and severe obesity in individuals with Bardet-Biedl syndrome (BBS) or Alström syndrome

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services (CMS) to participate in the Medicaid National Drug Rebate Program (NDRP), providing access to Phexxi® (lactic acid, citric acid and potassium bitartrate) for the Medicaid population effective January 1, 2021.